NCT07604233 2026-05-22Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AMLM.D. Anderson Cancer CenterPhase 1/2 Not yet recruiting30 enrolled
NCT04260022 2025-11-05Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLAscentage Pharma Group Inc.Phase 1 Recruiting242 enrolled